

FIVE PRIME THERAPEUTICS INC

Form 8-K

January 07, 2019

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 7, 2019**

**Five Prime Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(state or other jurisdiction of**  
**incorporation)**

**001-36070**  
**(Commission File Number)**

**26-0038620**  
**(I.R.S. Employer Identification**  
**No.)**

**111 Oyster Point Boulevard**  
**South San Francisco, California**

**94080**  
**(Zip Code)**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (415) 365-5600**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicated by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

Five Prime Therapeutics, Inc. ( FivePrime ) is in the process of finalizing its financial results for the fiscal year ended December 31, 2018. Set forth below is a preliminary estimate of FivePrime s cash, cash equivalents and marketable securities as of December 31, 2018, based on information currently available as of the date of this Current Report on Form 8-K (this Current Report ).

FivePrime estimates that its cash, cash equivalents and marketable securities as of December 31, 2018 was approximately \$270.1 million. FivePrime s actual consolidated cash, cash equivalents and marketable securities as of December 31, 2018 may differ from these estimates due to the completion of FivePrime s year-end closing and auditing procedures.

**Item 7.01 Regulation FD Disclosure**

FivePrime expects that its net cash used in operating activities for fiscal year 2019 will be between \$117 and \$122 million. FivePrime expects that its cash, cash equivalents and marketable securities as of December 31, 2019 will be between \$148 and \$153 million.

The disclosures set forth in Item 2.02 of this Current Report are incorporated herein by reference.

The information provided in this Item 7.01 is furnished pursuant to Regulation FD and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Cautionary Note on Forward-looking Statements**

This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on FivePrime s expectations and assumptions as of the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include statements about FivePrime s (i) estimated cash, cash equivalents and marketable securities as of December 31, 2018; (ii) estimated net cash used in operating activities for fiscal year 2019; and (iii) estimated cash, cash equivalents and marketable securities as of December 31, 2019. Other factors that may cause FivePrime s actual results to differ from those expressed or implied in the forward-looking statements in this Current Report are discussed in FivePrime s filings with the U.S. Securities and Exchange Commission, including the Risk Factors sections contained therein. Except as required by law, FivePrime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Five Prime Therapeutics, Inc.**

By: /s/ Francis Sarena  
Francis Sarena  
Chief Strategy Officer and Secretary

Dated: January 7, 2019